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Most small cell lung cancers (SCLC) coexpress the c-kit protein tyrosine receptor kinase and its ligand stem cell factor, resulting in an
autocrine loop. As SCLC growth is also driven by insulin-like growth factor-1 receptor (IGF-1R) signalling, tyrphostins AG 1024 and
1296 (inhibitors of IGF-1R and c-kit activity, respectively) were used to co-target these receptors in H 209 SCLC cells. Combination
treatment caused synergy in proliferation inhibition and in apoptosis induction, and also enhanced reduction in phosphorylation of
Erk1/Erk2, suggesting that co-targeting IGF-1R and c-kit in SCLC may be more effective than single-agent therapies.
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The signalling activity of receptor protein tyrosine kinases (PTKs)
tightly controls crucial cellular processes such as apoptosis,
differentiation and proliferation, and it is therefore not surprising
that deregulation of these molecules often leads to neoplastic
progression. The involvement of PTKs in the pathology of many
cancers has brought attention to these receptors as potential
targets for therapeutic intervention (Morin, 2000; Shawver et al,
2002; Dancey and Sausville, 2003). Some neoplastic conditions
result from excessive activity of a single PTK (Bcr-Abl in chronic
myeloid leukaemia (Melo, 1996), c-kit or PDGFRA in gastro-
intestinal stromal cell tumours (Hirota et al, 1998; Heinrich et al,
2003)), and are effectively treated using the PTK inhibitor Imatinib
(STI 571, Gleevec) (Druker et al, 2001; van Oosterom et al, 2001).
However, most cancers involve dysfunction of more than one PTK
and crosstalk between their downstream signalling pathways. A
therapeutic approach to address this issue involves co-targeting
different PTKs (Wu et al, 1995; Ye et al, 1999; Moasser et al, 2001;
Moulder et al, 2001; Lu et al, 2001; Chakravarti et al, 2002; Totpal
et al, 2002; Camirand et al, 2002). For co-targeting approaches to
be useful, careful consideration must be given to the choice of
PTKs to be simultaneously blocked (Dancey and Sausville, 2003).
Small cell lung cancer (SCLC) is an aggressive cancer with poor
prognosis, which readily metastasises outside the chest, and has a
median survival of approximately 9 months (Chute et al, 1999).
SCLC has been treated with traditional combination chemotherapy
since the 1970s, but less than 3% of patients with extensive-stage
SCLC survive more than 3 years (Chute et al, 1999). The molecular
pathology of more than 70% of SCLC cases involves autocrine
stimulation due to the coexpression of c-kit and its ligand stem cell
factor (SCF) (Hibi et al, 1991), and high c-kit expression level is
associated with a poor prognosis (Micke et al, 2003). Imatinib
(which targets Bcr-Abl, c-kit, and PDGFR (Morin, 2000)), tyrphostin
AG 1296 (which inhibits c-kit and PDGFR (Kovalenko et al,1 9 9 4 ) )
and indolinones SU 5416 and SU6597 (inhibitors of c-kit and related
kinases (Krystal et al, 2001)) reduce SCLC proliferation in vitro
(Krystal et al, 1997, 2000, 2001; Wang et al,2 0 0 0 ;K i j i m aet al, 2002).
Phase I and II clinical trials with Imatinib are ongoing for SCLC.
Another growth pathway known to sustain proliferation in SCLC
is the IGF-1R signalling cascade (Nakanishi et al, 1988; Macaulay
et al, 1990). In many cancers, IGF-1R signalling leads to activation of
PI-3K and MAPK pathways, stimulates proliferation, promotes
angiogenesis and metastasis, and inhibits apoptosis (Khandwala
et al, 2000; Pollak, 2000; Yu and Rohan, 2000; Wang and Sun, 2002).
Preclinical work has demonstrated that IGF-1R could be used as a
successful co-target with EGFR (Chakravarti et al, 2002) and HER2/
erbB2 (Lu et al, 2001; Camirand et al, 2002), and in the latter study,
synergistic inhibition of proliferation was observed in co-targeted
breast cancer cells. The availability of several novel inhibitors of
IGF-1R signalling (Ludwig et al, 2003; Garcia-Echeverria et al,2 0 0 3 ;
Mitsiades et al, 2003) implies that clinical exploitation of any
synergism between co-targeting of c-kit and IGF-1R will be practical.
In this study, we use tyrphostins AG 1024 (IGF-1R inhibitor)
and AG 1296 (PDGFR and c-kit inhibitor) to inhibit PTK activity in
H 209 SCLC cells which present no PDGFR receptors. We
demonstrate that combination treatment causes synergy in
inhibition of proliferation and in apoptosis induction in these
cells, and we speculate that co-targeting the IGF-1R and c-kit
signalling pathways is potentially a more effective approach for
this system than single-agent therapies.
MATERIALS AND METHODS
Cell culture and proliferation assays
H 209 SCLC cells were obtained from ATCC (Manassas, VA, USA)
and cultured at 371C with 5% CO2 in RPMI 1640 medium with 10%
foetal bovine serum (FBS) (InVitrogen, Gaithersburg, MD, USA)
except in growth inhibition assays where the FBS supplement was
reduced to 1%. Cell proliferation was measured with the Alamar
Blue dye reduction method (Biosource International, Camarilo,
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sCA, USA), which is optimal for cells growing in anchorage-
independent conditions. Tests were conducted with 10
4cellswell
 1
in 200ml media in 96-well plates (edge wells were not used, but
filled with 200ml PBS) and three replicates per dose combination
were used for each experiment. Stock solutions (10mM) in DMSO
of tyrphostins AG 1024 and AG 1296 (Calbiochem, San Diego, CA,
USA) were kept at  201C and diluted in 1% medium just before
use. DMSO concentration in final culture was kept below 0.2%
(vv
 1). All procedures involving tyrphostins were conducted in
low light intensity.
Detection of surface receptors
H 209 cells were collected by centrifugation and washed with FACS
buffer 41C (PBS containing 3% FBS and 0.02% NaN3). Approxi-
mately 10
6cells were stained with phycoerythrin (PE)-conjugated
anti-IGF-1R, anti-PDGFRa, or PDGFRb antibodies (BD Pharmin-
gen, San Diego, CA), or with fluorescin (FITC)-conjugated anti-c-
kit (CD 117) antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Cells were incubated with the antibodies for 30min at 41Ci n
the dark, washed twice, and resuspended in FACS buffer. Analysis
was conducted for 20000 cells using a FACSCalibur flow cytometer
(BD Biosciences, Burlington, MA, USA) with CellQuest software
(BD Biosciences Immunocytometry Systems, Franklin Lakes, NJ,
USA). Normal mouse IgG1 (Santa Cruz Biotechnologies) was used
for isotype determination.
Cell cycle analysis
Approximately 10
6cells were collected by centrifugation, washed
twice in PBS and fixed in ice-cold 70% ethanol for 1h, then stained
for 30min in the dark at 371C in 1ml propidium iodide (PI)
staining buffer (0.1% Triton X-100, 0.1mM EDTA pH 7.4 in PBS, to
which 50mgml
 1 PI and 0.05mg RNAse were added just before
use). DNA staining was determined by flow cytometry on a
FACSCalibur using CellQuest software (see previous section).
Induction of apoptosis
Approximately 10
6cells were collected by centrifugation
and washed in PBS, then stained with annexin-V-FITC and
with PI using the ApoTarget kit (Biosource International,
Camarillo, CA, USA). Analysis was conducted by flow cytometry
on a FACSCalibur using CellQuest software (see receptor section
above).
Western blots
H 209 cells (approx. 3 million) were treated with various doses of
tyrphostins or vehicle for a period of 72h. Cells were lysed in
nondenaturing buffer (1% Nonidet NP-40, 20mM Tris-Cl pH 8.0,
0.5mM Na orthovanadate pH 9.0 and proteinase inhibitors (Roche,
Mannheim, Germany), and freeze-thawed 3 times. Insoluble
material was removed by centrifugation, and 50mg aliquots of
the supernatant were separated on 12% polyacrylamide gels. After
transfer to TransBlot nitrocellulose membranes (BioRad, Hercules,
CA, USA), the proteins were reacted O/N with the following
primary antibodies: anti-Akt, anti-phospho-Akt (ser 473), anti-
Erk1/Erk2 (p44/42), and anti-phospho Erk1/Erk2 (Thr202/Tyr204)
(Cell Signalling, Beverly, MA, USA) at 1:1000 dilution, then 1h
with 1:2000 horseradish peroxidase-conjugated anti-rabbit im-
munoglobulin G (Pharmacia-Amersham, Piscataway, MJ, USA).
Blots were reacted with the ECL chemoluminescence kit (Pharma-
cia-Amersham, Piscataway, NJ, USA) and exposed to X-OMAT LS
film (Kodak, Rochester, NJ, USA). Densitometry analysis was
conducted using the Scion Image software (Scion Corp., Frederick,
MD, USA).
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Figure 1 Surface expression of IGF-1R, c-kit, PDGFR a, and PDGFR b on H 209 SCLC cells. H 209 cells collected by centrifugation were stained with
phycoerythrin (PE)-conjugated anti-IGF-1R, anti-PDGFR a, anti-PDGFR b antibodies, or fluorescein (FITC)-conjugated anti-c-kit (CD 117) antibody (shaded
peaks). Flow cytometry analysis reveals the presence of IGF-1R and c-kit but absence of PDGFR receptors. Normal mouse IgG1 was used for isotype
determination (open peaks). Positive controls for anti-PDGFR a and b antibodies were in robust primary cells and TC-71 Ewing’s sarcoma cells, respectively
(not shown). Counts indicate number of events.
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H 209 cells express no PDGF receptors, but present both c-kit
(Kijima et al, 2002) and IGF-1R (Nakanishi et al, 1988; Quinn et al,
1996), as analysed by flow cytometry (Figure 1). Treatment with
tyrphostins as single agents revealed an IC50 for inhibition of cell
proliferation of 3.7570.8mM for AG 1024, and 21.573.3mM for AG
1296. These two inhibitors were used in a matrix of combinations,
and an isobologram plot (Berenbaum, 1981) for IC50 demonstrated
synergistic interactions in growth inhibition (Figure 2A). Combi-
nation index (CI) values for several combination treatments were
calculated from the classic isobologram equation and proved
significantly smaller than 1, indicating synergy. Combination
treatments showed no synergy of action on the status of any phase
of the cell cycle, as observed by flow cytometry after propidium
iodide staining of ethanol-fixed cells (results not shown). In
contrast, the synergy in growth reduction was observed to parallel
a synergy in apoptosis induction (IC75 CI¼0.62 at AG 1024 2.5mM
and AG 1296 5.0mM, Figure 2B), pointing to a cytotoxic effect in
these cancer cells associated with the co-targeting of IGF-1R and
c-kit.
At concentrations where apoptosis is induced synergistically
by combinations of the two inhibitors, co-treatment did not
enhance inhibition of Akt phosphorylation over levels observed
after treatment with AG 1024 alone (results not shown). However,
co-treatment reduced the phosphorylation level of p44/42 (Erk1/
Erk2) by 60% with respect to control (Figure 2C).
DISCUSSION
In this study, tyrphostins AG 1024 (IGF-1R inhibitor) and AG 1296
(PDGFR and c-kit inhibitor) were used in combination for
treatment of H 209 SCLC cells. Since specificity of tyrphostin
action is not strict, (for example, AG 1296 inhibits c-kit, PDGFR a
and PDGFR b with similar Kds (Kovalenko et al, 1994)), we
demonstrated the absence of PDGF receptors in the target cells,
and confirmed the presence of IGF-1R and c-kit. The data
presented here indicate that in H 209 SCLC cells, blockade
of IGF-1R signalling synergistically enhances the antiproliferative
effects of an anti-c-kit strategy, and that while both anti-IGF-1R
and anti-c-kit strategies as single agents can induce apoptosis in
this system, combination treatment results in synergy of apoptotic
induction. Future work will determine whether these observations
can be extended to more SCLC cell lines and have relevance to in
vivo behaviour of SCLC.
Cellular pathways by which this observed synergy is achieved
may involve downstream effectors differentially influenced by the
inhibition of IGF-1R and c-kit. Akt/PKB, an important component
of the P1-3K-mediated signal route, is involved in several human
cancers, and has recently been shown to be important in the
progression of lung cancer (Krystal et al, 2002; Chun et al, 2003).
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Figure 2 Synergy of IGF-1R and c-kit-targeting treatments. (A)
Isobologram plot at IC50 and combination index (CI) of the effects of
AG 1094 and AG 1296 on H 209 SCLC cell growth. Tests were conducted
in triplicates with 10
4 cells treated with tyrphostins singly or in combination
for a total of 72h in RPMI with 1% FBS, and proliferation of the anchorage-
independent cells was assayed by Alamar blue dye reduction (shown is
an experiment representative of five). Proliferation CI values were
calculated using the classic isobologram equation (Berenbaum, 1981)
and are indicated on a graph. CI values o1 indicate synergy. Single-agent
dose–response curves on H 209 cell growth for individual tyrphostins
are shown on the right. (B) Apoptosis in H 209 cells treated with
tyrphostins AG 1024 (0, 0.25, 2.5mM) and AG 1296 (0, 2.5, 5.0mM)
independently or in combination for a total of 72h in 3ml RPMI 1% FBS in
six-well plates. Cells were collected by centrifugation, washed in PBS, and
stained with annexin V-FITC and PI, and analysed by flow cytometry.
Annexin-V-positive cells (M1 peak) represent apoptotic populations.
Number above M1 peak is the increase in the percentage of apoptotic
cells over the basal control level (Cntrl¼34.5%), (shown is one of two
experiments producing similar results). (C) Modification of phosphorylation
levels of Erk1/Erk2 in H 209 cells treated for 72h in media containing 1%
FBS with 1.0mM AG 1024, and/or 5.0mM AG 1296. Western blot analysis
was conducted on 50-mg protein aliquots with anti Erk1/Erk2 (p44/42) and
anti-phospho Erk1/Erk2 (Thr202/Tyr204) primary antibodies and HRP-
conjugated anti-rabbit IgG, and revealed with the ECL chemoluminescence
reaction. Densitometric analysis of the bands is shown below. C: control
cells treated with vehicle (shown is one of two experiments producing
similar results).
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below levels obtained by AG 1024 inhibition, however, reduction in
the phosphorylation of Erk1/Erk2 was enhanced by co-targeting,
suggesting that combination of the IGF-1R and c-kit inhibitors (at
lower concentrations than needed for single-agent activity) acts
through this kinase to promote the greater-than-additive apoptotic
effects observed.
It is tempting to speculate that the antiapoptotic effects of IGF-1
hinder cancer therapies that target other PTKs, and that the
antineoplastic effects observed when blocking a PTK may be
significantly underestimated if examined only under conditions
where IGF-IR is fully functional. Previous work indicates that the
in vivo targeting of IGF-1R not only has antineoplastic activity
(Arteaga et al, 1989; Andrews et al, 2001) but is well-tolerated
(Hofmann et al, 2003). These observations, taken together with our
results, suggest that combining anti-IGF-1R and anti-kit targeting
may be therapeutically useful in SCLC treatment. Targeted single-
agent PTK therapies are effective in cancers where activation by
mutation of one particular receptor is responsible for neoplastic
progression (Druker et al, 2001; van Oosterom et al, 2001; Heinrich
et al, 2002); however, in the more common situations where
overexpression or deregulation of multiple PTKs are involved,
combination approaches may prove to be of value and the IGF-1
receptor appears as a promising co-target.
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